Sentinel’s “IMPACT” Beyond Safety: Anti-Coagulant Study Is Early Test
This article was originally published in RPM Report
Executive Summary
The Sentinel post-marketing surveillance system is up and running. Now, FDA is ready to explore uses beyond safety.
You may also be interested in...
Real World Evidence Benefits, Limits Explored In US FDA Demonstrations
FDA's Jacqueline Corrigan-Curay lists three demonstrations now underway that are aimed at looking at different aspects of generating real world evidence and may inform the agency's evaluation of the data and methods.
Sentinel May Expand To Generic Equivalence Studies
Tool being designed for rapid queries of US Sentinel data to consider generic drug switches, potentially spot equivalence problems.
Sentinel May Expand To Generic Equivalence Studies
Tool being designed for rapid queries of US Sentinel data to consider generic drug switches, potentially spot equivalence problems.